A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy Participants

In brief

This study is to evaluate the safety, pharmacokinetics/pharmacodynamics (PK/PD), food-effect, and drug-drug interaction study of ACP-196 in healthy participants.

Key facts

Study ID

NCT04901923

Run by

Acerta Pharma BV

People needed

59

Starts

2014-03-15

Expected to finish

2014-05-22

Last updated by the study team

2021-05-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Body mass index (BMI) >=18.0 and <=30.0 kg/m\^2.
• Healthy as determined by medical history and physical examination.
• Nonsmoker
• Normal clinical laboratory test results and ECG, or results with minor deviations which are not considered to be clinically significant in the judgment of the investigator.
• Men of and women of childbearing potential to follow protocol defined contraception methods.
• Women must have negative urine pregnancy test.
• Willingness and ability to swallow study drug capsules.

You may not qualify if…

• Prior or ongoing clinically significant illness, medical condition, medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the subject; alter the absorption, distribution, metabolism, or excretion of the study drug; or impair the assessment of study results.
• Evidence of ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections).
• Women cannot be pregnant or breast feeding.
• Significant history of drug or alcohol abuse or addiction within 3 years before study screening or as evidenced by continuing medical complications of prior drug or alcohol use.
• History of blood or plasma donation within 90 days before first study drug administration.
• Currently drinking over 21 units/week of ethanol
• Drug toxicology screen positive for any prohibited drugs, illicit substances, or alcohol.
• Anticipated need for alcohol, tobacco, or any drug during the study drug administration and immediate follow-up periods.
• Relative to admission has any of the following exposures: has taken a prescription systemic medication within 14 days; has used an over-the counter systemic medication (other than acetaminophen) within 7 days; has ingested calcium supplements or calcium-containing vitamins within 7 days; has ingested grapefruit, grapefruit juice, or grapefruit-containing products within 7 days; has consumed alcohol within 48 hours; has taken acetaminophen within 24 hours.
• Positive test for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen or hepatitis B core antibody, or hepatitis C antibody.
• Unwillingness to avoid vigorous physical activity during inpatient clinic confinements.
• Part 2 only - Inability or unwillingness to eat all of the ingredients of the high-fat, high-calorie meal as specified in the protocol.
• Part 3 only - Known allergy to itraconazole or other azole compounds.

Where it is running

• Celerion — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.